Twitxy Saved

Journal of Cardiovascular Pharmacology

Verified account This account is verified. Learn more

@JCVPOnline

Founded in 1979, JCVP is a monthly published journal.

Editor-in-Chief: George W. Booz, Ph.D.
Social Media Coordinator: Raffaele Altara, Ph.D.
USA journals.lww.com/cardiovascular… Joined October 2018
1.8K Following 2.2K Followers 530 Posts

Latest posts 5

Journal of Cardiovascular Pharmacology Verified account @JCVPOnline
Can we stop aspirin after just one month of DAPT following PCI without compromising ischaemic safety?
An analysis of 11 randomized trials involving 37,443 patients found that P2Y12-inhibitor monotherapy substantially reduced bleeding, with broadly comparable ischaemic outcomes following one- versus three-month aspirin withdrawal. However, an early ischaemic signal with near-immediate withdrawal highlights the importance of timing.
Does the future of post-PCI antiplatelet therapy lie in earlier aspirin withdrawal?
Read the study and share your perspective!
#Cardiology #CardioTwitter #PCI #AntiplateletTherapy #InterventionalCardiology

pubmed.ncbi.nlm.nih.gov/42832633
@drhbulluck
3 replies 9 reposts 30 likes 2.7K views View on X
Journal of Cardiovascular Pharmacology Verified account @JCVPOnline
Could targeting innate immunity change how we approach lupus-associated pericarditis?
Emerging evidence suggests that IL-1 blockade may offer a promising therapeutic approach for patients with SLE-associated pericarditis refractory to conventional treatment. Could identifying an IL-1-driven inflammatory phenotype help us move toward more personalized cardiovascular care?
Read the commentary and share your thoughts!
#Cardiology #CardioTwitter #Pericarditis #Lupus #Immunopharmacology

pubmed.ncbi.nlm.nih.gov/42766859
@aldobonaventura; @marchetta97560; @luigiadamomdphd
0 replies 4 reposts 10 likes 410 views View on X
Journal of Cardiovascular Pharmacology Verified account @JCVPOnline
🏆 #JCVPTopPosts – Q3 2026
Here are the most impactful posts from @JCVPonline this quarter:
1️⃣ Prednisone in the Management of Pericarditis: A Systematic Review
x.com/JCVPOnline/sta…

2️⃣ A Comprehensive Review of PCSK9 Inhibitor Therapy
x.com/JCVPOnline/sta…

3️⃣ Triple Antithrombotic Therapy for the Prevention of Left Ventricular Thrombus Following Anterior ST-Elevation Myocardial Infarction: A Systematic Review and Meta-Analysis
x.com/JCVPOnline/sta…
📌 Follow #JCVPTopPosts to stay updated on trending cardiovascular pharmacology research!
🔗 Read more: Link to journal
#CardiovascularPharmacology #BiomedicalResearch #ClinicalResearch
Journal of Cardiovascular Pharmacology Verified account @JCVPOnline Aug 16
How will the next generation of PCSK9-targeted therapies change the way we prevent cardiovascular disease?
This comprehensive review examines the evolving landscape of PCSK9 inhibitor therapy, from established monoclonal antibodies with proven cardiovascular benefits to newer agents like inclisiran and emerging oral therapies. It also explores which high-risk patients may benefit most and discusses expanding indications for primary prevention alongside ongoing challenges in equitable implementation. Which advances do you think will have the greatest impact on clinical practice? Join the conversation.
#PCSK9 #LipidManagement #ASCVD #PreventiveCardiology #CardioTwitter

pubmed.ncbi.nlm.nih.gov/42391098
@jaideeppatelmd, @doctormarvelMD, @akulkarniMD @ciccaronecenter @hopkinsmednews
View quoted post on X
Journal of Cardiovascular Pharmacology Verified account @JCVPOnline
Could dapagliflozin help limit alcohol-related cardiac injury?
In a rat study, high-dose dapagliflozin was associated with less alcohol-related heart tissue damage and improvements in markers of inflammation and oxidative stress. The findings are promising, but they come from an animal model and need further study. What should researchers investigate before considering clinical relevance? Share your perspective or retweet to invite discussion.
#Cardiology #CardioTwitter #Dapagliflozin #CardiacInjury #CardiovascularResearch

pubmed.ncbi.nlm.nih.gov/42696673
Journal of Cardiovascular Pharmacology Verified account @JCVPOnline
Could the subclinical phase be a critical window to protect the heart in Duchenne muscular dystrophy?
A meta-analysis of 14 studies and 1,788 patients found that cardioprotective therapy started before overt ventricular dysfunction was associated with lower mortality and less cardiac progression. Short-term ejection fraction did not significantly change, underscoring that early benefits may not show up in this measure alone. What outcomes should future studies prioritize? Share your perspective or retweet to bring the community into the discussion.
#Cardiology #CardioTwitter #DuchenneMuscularDystrophy #Cardiomyopathy #CardiovascularResearch

pubmed.ncbi.nlm.nih.gov/42520762